Clinical trial
Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)
NCT07148297 is registered in ClinicalTrials.gov with Epiliquid Holding, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)
- Lead sponsor
- Epiliquid Holding, Inc
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- June 30, 2021
- Completion date
- December 31, 2026
- Enrollment
- 600 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colo-rectal cancer